Prognostic value of single nucleotide polymorphisms of candidate genes associated with inflammation in early stage breast cancer

Breast Cancer Research and Treatment

Volumn 138, Issue 3, 2013, Pages 917-924

  Murray, James L ^a   Thompson, Patricia ^b   Yoo, Suk Young ^a   Do, Kim Anh ^a   Pande, Mala ^a   Zhou, Renke ^a,c   Liu, Yanhong ^c   Sahin, Aysegul A ^a   Bondy, Melissa L ^a,c   Brewster, Abenaa M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Breast cancer; Gene polymorphisms; Inflammation

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AFRICAN AMERICAN; AGE; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; EARLY CANCER; EUROPEAN AMERICAN; FEMALE; GENE; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HETEROZYGOTE; HISPANIC; HOMOZYGOTE; HUMAN; HUMAN TISSUE; IL13 GENE; IL4 GENE; MAJOR CLINICAL STUDY; NFKB1 GENE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

AFRICAN AMERICANS; BREAST NEOPLASMS; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HISPANIC AMERICANS; HOMOZYGOTE; HUMANS; INFLAMMATION; INFLAMMATORY BREAST NEOPLASMS; INTERLEUKIN-13; INTERLEUKIN-4; INTERLEUKIN-4 RECEPTOR ALPHA SUBUNIT; LINKAGE DISEQUILIBRIUM; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NF-KAPPA B P50 SUBUNIT; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84877809770     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2445-x     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225-249
2. Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B et al (2008) Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 100(16):1179-1183
3. Cianfrocca M, Goldstein LJ (2004) Prognostic and predictive factors in early-stage breast cancer. Oncologist 9(6):606-616
4. Le Doussal V, Tubiana-Hulin M, Friedman S, Hacene K, Spyratos F, Brunet M (1989) Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1,262 invasive ductal breast carcinomas. Cancer 64(9):1914-1921
5. Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN (2003) Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 78(1):105-118
6. Menard S, Fortis S, Castiglioni F, Agresti R, Balsari A (2001) HER2 as a prognostic factor in breast cancer. Oncology 61(Suppl 2):67-72
7. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869-10874
8. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747-752
9. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K et al (2004) Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2(2):E7
10. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C (2007) An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 8(8):R157
11. Yau C, Esserman L, Moore DH, Waldman F, Sninsky J, Benz CC (2010) A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res 12(5):R85
12. Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK et al (2010) Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J Clin Oncol 28(28):4316-4323
13. Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436-444
14. Le Marchand L, Haiman CA, van den Berg D, Wilkens LR, Kolonel LN, Henderson BE (2004) T29C polymorphism in the transforming growth factor beta1 gene and postmenopausal breast cancer risk: the Multiethnic Cohort Study. Cancer Epidemiol Biomarkers Prev 13(3):412-415
15. Smith KC, Bateman AC, Fussell HM, Howell WM (2004) Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet 31(4):167-173
16. Balasubramanian SP, Azmy IA, Higham SE, Wilson AG, Cross SS, Cox A et al (2006) Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review. BMC Cancer 14(6):188
17. Kim S, Hagemann A, DeMichele A (2009) Immuno-modulatory gene polymorphisms and outcome in breast and ovarian cancer. Immunol Invest 38(3-4):324-340
18. Brewster AM, Do K-A, Thompson PA, Hahn KM, Sahin AA, Cao Y, Stewart MM, Murray JL, Hortobagyi GN, Bondy ML (2008) The relationship between epidemiological risk factors and breast cancer recurrence. J Clin Oncol 25(28):4438-4444
19. Pounds S, Morris SW (2003) Estimating the occurrence of false positive and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-values. Bioinformatics 19:1236-1242
20. Binder H, Schumacher M (2008) Allowing for mandatory covariates in boosting estimation of sparse high-dimensional survival models. BMC Bioinformatics 9:1-10
21. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2):263-265
22. Ghosh S, Karin M (2002) Missing pieces in the NF-kappaB puzzle. Cell 109(Suppl):S81-S96
23. Nakshatri H, Goulet RJ Jr (2002) NF-kappaB and breast cancer. Curr Probl Cancer 26(5):282-309
24. Nelson DE, Ihekwaba AE, Elliott M, Johnson JR, Gibney CA, Foreman BE et al (2004) Oscillations in NF-kappaB signaling control the dynamics of gene expression. Science 306(5696):704-708
25. Barkett M, Gilmore TD (1999) Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 18(49):6910-6924
26. Kurt RA, Urba WJ, Smith JW, Schoof DD (1998) Peripheral T lymphocytes from women with breast cancer exhibit abnormal protein expression of several signaling molecules. Int J Cancer 78:16-20
27. Baumgarten SC, Frasor J (2012) Minireview: inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers. Mol Endocrinol 26(3):360-371
28. Hageman T, Lawrence T, McNeish I, Charles KA, Kulbe H, Thompson RG, Robinson SC, Balkwill FR (2008) "Re-educating" tumor-associated macrophages by targeting NF-kB. J Exp Med 206:1261-1268
29. Kelly PM, Davison RS, Bliss E (1988) McGee J0. Macrophages in human breast disease: a quantitative immunohistochemical study. Br J Cancer 57:174-177
30. Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB et al (2004) NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 101(27):10137-10142
31. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ, Sledge GW (1997) Constitutive activation of NF-kB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17:3629-3639
32. de Graffenried LA, Chandrasekar B, Friedrichs WE, Donzis E, Silva J, Hidalgo M, Freeman JW, Weiss GR (2004) NF-kB inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to Tamoxifen. Ann Oncol 15:885-890
33. Riggins RB, Zwart A, Nehra R, Clarke R (2005) The nuclear factor kB inhibitor parthenolide restores ICI 182,780 (Fasolodex, fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. Mol Cancer Ther 4:33-41
34. Van Dyke AL, Cote ML, Wenzlaff AS, Land S, Schwartz AG (2009) Cytokine SNPs: comparison of allele frequencies by race and implications for future studies. Cytokine 46(2):236-244
35. Erdei E, Kang H, Meisner A, White K, Pickett G, Baca C, Royce M, Berwick M (2010) Polymorphisms in cytokine genes and serum cytokine levels among New Mexican Women with and without breast cancer. Cytokine 51:18-24
36. De Nardo DG, Coussens LM (2007) Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2(4):212
37. Schoof N, von Bonin F, Zeynalova S, Ziepert M, Jung W, Loeffler M, Pfreundschuh M, Trumper L, Kube D (2009) Favorable impact of the interleukin-4 receptor allelic variant I75 on the survival of diffuse large B-cell lymphoma patients demonstrated in a large prospective clinical trial. Ann Oncol 20(9):1548-1554
38. Aspord C, Pedroza-Gonzalez A, Gallegos M, Tindle S, Burton EC, Su D et al (2007) Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med 204(5):1037-1047
39. Martin AM, Athanasiadis G, Greshock JD, Fisher J, Lux MP, Calzone K et al (2003) Population frequencies of single nucleotide polymorphisms (SNPs) in immuno-modulatory genes. Hum Hered 55(4):171-178
40. Haukim N, Bidwell JL, Smith AJ, Keen LJ, Gallagher G, Kimberly R et al (2002) Cytokine gene polymorphism in human disease: on-line databases, supplement 2. Genes Immun 3(6):313-330
41. Guida E, Stewart A (1998) Influence of hypoxia and glucose deprivation on tumour necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor expression in human cultured monocytes. Cell Physiol Biochem 8(1-2):75-88
42. Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR (1994) Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue. Int J Cancer 56(6):777-782
43. Jung JH, Chae YS, Moon JH, Kang BW, Kim JG, Sohn SK, Park JY, Lee MH, Park HY (2010) TNF superfamily gene polymorphism as prognostic factor in early breast cancer. J Cancer Res Clin Oncol 136(5):685-694
44. Mestiri S, Bouaouina N, Ahmed SB, Khedhaier A, Jrad BB, Remadi S et al (2001) Genetic variation in the tumor necrosis factor-alpha promoter region and in the stress protein hsp70-2: susceptibility and prognostic implications in breast carcinoma. Cancer 91(4):672-678
45. Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS, Hortobagyi GN (2004) Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25(3):94-102
46. Demaria S, Pikarsky E, Karin M, Coussens LM, Chen YC, El-Omar EM et al (2010) Cancer and inflammation: promise for biologic therapy. J Immunother 33(4):335-351